slno stock — SLNO (Soleno Therapeutics, Inc.)
SLNO (Soleno Therapeutics, Inc.) — Stock
SLNO stock is the Nasdaq ticker for Soleno Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing therapies for rare metabolic and neurobehavioral disorders. This article summarizes the company profile and the publicly traded equity (SLNO stock), covering trading details, management, core product programs, regulatory and commercialization milestones, financial reporting, analyst coverage, risk factors and where investors and researchers can find up‑to‑date market and clinical information.
Company overview
Soleno Therapeutics, Inc. is a clinical‑stage biopharmaceutical company focused on developing treatments for rare diseases with high unmet medical need. The company’s lead programs historically targeted syndromes characterized by hyperphagia and neurobehavioral features, using small‑molecule approaches designed to modulate metabolic and neuronal pathways.
Headquartered in the United States, Soleno was founded in the 2000s and has operated as a small‑cap public company on Nasdaq. As of the most recent publicly available SEC filings and company disclosures, the company has been led by a management team with experience in biotech development and commercialization. For current CEO name, management bios, and employee count, consult the company’s investor relations materials and Form 10‑K/10‑Q filings; these items are the authoritative sources for leadership and headcount figures.
Soleno’s therapeutic strategy centers on advancing clinical candidates from proof‑of‑concept studies through pivotal trials, with a focus on disorders such as Prader–Willi Syndrome and related indications where regulatory pathways for orphan drugs and rare disease approvals may be available. Commercial strategy has historically emphasized specialty channel commercialization and partnerships for distribution, once regulatory approvals are achieved.
Ticker and market listing
SLNO stock trades on the Nasdaq Global Market under the ticker symbol SLNO. Standard identifiers include the company’s CUSIP and ISIN; these can be found in the company’s filings and on major market data platforms. Typical Nasdaq trading hours apply: regular session trading from 9:30 a.m. to 4:00 p.m. Eastern Time, with pre‑market and after‑hours sessions available through many brokers and market data vendors.
Real‑time quotes for SLNO stock are available from market data providers and exchanges. For authoritative market data and historical trade records consult Nasdaq official data feeds and the company’s filings. Retail platforms and market data websites also provide quote pages, charting, and trading metrics; for active trading and order execution, consider regulated broker‑dealers and the Bitget trading platform.
Business operations and product pipeline
Soleno’s pipeline has been anchored by controlled‑release formulations of diazoxide choline, often referred to by the development code DCCR, and in some materials by commercial names such as VYKAT XR where applicable. The primary indications targeted have included Prader–Willi Syndrome (PWS) and other rare metabolic and neurobehavioral disorders characterized by hyperphagia, obesity risk and behavioral symptoms.
The company’s programs have focused on reformulating an active moiety to achieve sustained pharmacokinetic profiles intended to reduce hyperphagia and improve behavioral outcomes. Development efforts have progressed through proof‑of‑concept studies, randomized controlled trials and open‑label extensions. The company has also explored additional indications or label expansions that leverage the same mechanism of action.
Lead product(s) and clinical status
DCCR (diazoxide choline controlled‑release): DCCR is Soleno’s lead candidate. Mechanism of action: diazoxide is a potassium channel opener that can reduce neuroendocrine‑driven hyperphagia by modulating neuronal and hypothalamic signaling pathways. The controlled‑release formulation aims to provide stable plasma concentrations to balance efficacy and tolerability.
Clinical stage: Historically, DCCR advanced through Phase 2/3 development programs and randomized trials in patients with Prader–Willi Syndrome and related disorders. Key trials included randomized, double‑blind studies and open‑label extensions intended to evaluate efficacy on hyperphagia, behavioral scales, body composition and metabolic parameters. Major clinical results and safety data were reported in company press releases, clinical trial registries and peer‑reviewed outlets where applicable.
Published study references and clinical trial identifiers: pivotal and supportive trial data are indexed on clinical trial registries and in sponsor disclosures. For trial identifiers (NCT numbers), primary publications and post‑hoc analyses, consult the clinicaltrials.gov registry and the company’s scientific publications list in investor materials.
Regulatory and commercialization milestones
Regulatory interactions: Soleno has engaged with regulatory agencies such as the U.S. Food and Drug Administration (FDA) regarding development plans, trial design and potential marketing pathways for DCCR. Major regulatory milestones typically include End‑of‑Phase 2 meetings, pivotal trial submissions, NDA/BLA prospects (as applicable), and Advisory Committee interactions if convened.
Approvals and delays: As a clinical‑stage company, Soleno’s regulatory timetable depends on trial outcomes and regulatory reviews. Any approvals, complete response letters (CRLs), or other regulatory decisions are documented in company press releases and SEC filings. Reimbursement and market access discussions commonly follow approval and involve payers, specialty pharmacies and rare disease networks.
Commercialization readiness: For programs that approach potential approval, the company typically outlines commercialization plans including manufacturing scale‑up, distribution channels, patient support services and pricing strategy. Where applicable, Soleno has discussed partnerships to support market entry and scale.
Financial performance and results
As a clinical‑stage biopharma, Soleno’s historical revenue profile has been limited, with most reported ‘‘revenue’’ coming from milestone or collaboration payments if any, rather than product sales. Research‑and‑development expenses and general and administrative costs historically have been the primary drivers of operating losses.
Quarterly and annual results are reported in Form 10‑Q and Form 10‑K filings. These filings contain audited and unaudited financial statements providing details on cash on hand, R&D spend, operating loss, and balance sheet items such as debt or lease obligations. For the most current earnings highlights and management commentary, refer to the company’s latest earnings release and the investor presentation included in SEC filings.
Where to find filings: SEC EDGAR is the authoritative repository for the company’s 10‑K, 10‑Q, 8‑K and proxy filings. Investor relations materials on the company website provide slide decks, press releases and presentation recordings.
Key financial metrics
Important metrics for SLNO stock monitoring include market capitalization, revenue (if any), net income or net loss, earnings per share (EPS), cash and cash equivalents, burn rate, trading volume, 52‑week trading range, and analyst consensus estimates. These numbers change frequently and must be updated from primary market data sources and recent filings.
Note: exact numeric values for the above metrics are time‑sensitive. As of the company’s latest posted SEC filings, refer to those documents for precise figures. For market‑based metrics such as market cap and volume, consult Nasdaq and market data providers for real‑time updates.
Stock price history and trading activity
Historical performance: SLNO stock has historically shown the characteristic volatility of clinical‑stage biotech equities. Short‑term moves frequently track clinical readouts, regulatory announcements, and company financings. Long‑term performance depends on clinical success, commercial milestones and capital markets access.
Volatility and liquidity: Trading liquidity varies; average daily trading volume can fluctuate substantially around news events. Investors should anticipate that shares of small biotech companies can gap up or down on headlines and may display wider bid‑ask spreads versus large‑cap stocks.
Major price‑moving events
Events that tend to move SLNO stock include:
- Clinical trial readouts and topline results
- Regulatory decisions, filings, or communications from agencies like the FDA
- Company earnings releases and financial guidance updates
- Private or public financing announcements and equity offerings
- Partnerships, licensing agreements, or commercialization deals
- Insider transactions and significant changes in institutional ownership
- Major publications in peer‑reviewed journals or presentations at scientific conferences
Corporate actions and capital structure
Share structure: The company’s outstanding share count, authorized shares, and any preferred stock or convertible securities are enumerated in SEC filings. Dilution history is typically driven by equity offerings, stock‑based compensation and convertible financings. Any announced share repurchase programs, reverse splits, or other capital actions are disclosed publicly via press release and SEC filings.
Financing: Clinical‑stage biopharmas commonly raise capital through at‑the‑market offerings, registered direct placements, or convertible debt. When monitoring SLNO stock, review recent 8‑K filings for details on financings and the dilutive impact on share count.
Ownership, insiders and institutional holders
Institutional investors and insider holdings can signal confidence and influence float. Major institutional holders are listed in Form 13F filings and in the company’s proxy statement. Insider transactions (purchases or sales by executives and directors) are disclosed in Forms 4 and can be material for short‑term investor sentiment.
Trend tracking: Note whether insider ownership is increasing or decreasing and whether large institutions are initiating or trimming positions. Changes can reflect sentiment about upcoming catalysts or capital needs.
Analyst coverage and market sentiment
Analyst coverage for SLNO stock may be limited compared to large‑cap equities; coverage is often provided by specialty healthcare analysts and boutique equity research firms. Consensus ratings, if available, are aggregated on market data platforms. Published price targets and research notes should be used as context for understanding assumptions about trial outcomes, commercial potential and financing needs.
Retail and crowd sentiment: Social platforms, investor message boards and trading communities can influence near‑term momentum. Popular retail sentiment sources include equity discussion forums and ticker‑specific chat channels. Use these as complementary inputs rather than substitutes for primary filings and peer‑reviewed science.
Risks and investment considerations
Material risks for holders of SLNO stock include:
- Clinical risk: Failures or unfavorable results in clinical trials can materially affect the company’s prospects and share price.
- Regulatory risk: Even positive trial data does not guarantee regulatory approval; agencies may require additional data or deny approval.
- Commercialization and reimbursement risk: Securing payer coverage for rare‑disease therapies is complex and affects revenue potential.
- Competition: Other companies (and potential generics) working in overlapping indications may limit market share.
- Funding risk: Ongoing R&D requires capital; insufficient cash can lead to dilutive financings or program delays.
- Liquidity and volatility: Small‑cap biotech stocks often experience sharp price swings and wide spreads.
These risks make investment in clinical‑stage biotech speculative. This article provides informational context and not investment advice.
Governance and investor relations
Board composition: The company’s board typically includes members with backgrounds in biotech development, finance, and rare disease advocacy. Governance highlights including committee structures, executive compensation, and related‑party transactions are disclosed in the annual proxy statement.
Investor resources: Official investor relations resources include press releases, investor presentations, SEC filings and conference call transcripts. For the most accurate and current materials, consult the company’s investor relations page and the SEC EDGAR database. When following the company, prioritize primary sources for decisions and fact‑checking.
Recent notable news and developments
How to structure a timeline: For a chronological summary of recent material events that affected SLNO stock, organize items by date with a short descriptor and source. Important categories to include are trial readouts, regulatory letters, financings, earnings announcements, partnership deals, and executive changes.
Example of dated statements for context: As of 2024‑06‑01, according to the company’s SEC filings and public press releases, Soleno posted clinical trial updates and discussed financing plans in investor calls. For an up‑to‑date chronology, consult the company press release archive and 8‑K filings; each item should be recorded with the date and source.
Valuation and comparables
Approaches to valuing SLNO stock typically include scenario‑based discounted cash flow (DCF) models that account for probability‑adjusted approval and peak sales, and revenue‑multiple approaches referencing rare‑disease peers. Comparable companies are other clinical‑stage rare‑disease biotechs with similar commercial timelines, though direct comparables can be hard to find due to differences in indication, patent life and pricing potential.
When using comparables, match on variables like indication, targeted patient population size, route of administration, and development stage. For DCFs, build multiple scenarios (base, upside, downside) incorporating probabilities for pivotal success, time to market, pricing assumptions and discount rates appropriate for small biotech risk.
How to follow SLNO (data sources)
Recommended public data sources for ongoing price and fundamental updates include:
- Nasdaq (official quote and listing details)
- SEC EDGAR (company filings: 10‑K, 10‑Q, 8‑K, proxy materials)
- Company investor relations materials and press release archive
- Clinical trial registries for trial identifiers and protocol summaries
- Major market data platforms and charting tools for live quotes and historical charts
- Scientific journals and conference abstracts for published clinical results
For trading execution, consider regulated broker‑dealers and the Bitget trading platform. For custodial and wallet needs related to digital asset holdings, the Bitget Wallet is the recommended option. Note that securities trading and digital asset wallets are distinct services; evaluate each provider’s regulatory standing and product terms before use.
References and external links
The following sources were used for structure, factual framing and guidance on where to verify figures. For each reference below, consult the named source and the date accessed indicated:
- SEC EDGAR — company filings (10‑K, 10‑Q, 8‑K). Accessed 2024‑06‑01.
- Nasdaq — issuer and market data pages for SLNO. Accessed 2024‑06‑01.
- Company investor relations press releases and investor presentations. Accessed 2024‑06‑01.
- Clinical trial registries (clinicaltrials.gov) for trial identifiers and summaries. Accessed 2024‑06‑01.
- Peer‑reviewed journals and conference abstracts cited in company materials. Accessed 2024‑06‑01.
- Major market data aggregators and charting platforms for historical and intraday price action (access dates vary by platform; consult platform pages for timestamps).
Note: This article intentionally omits URLs. For exact documents and live market data, search the source names above combined with the company name "Soleno Therapeutics" or ticker "SLNO".
See also
- Biotechnology stocks and investment characteristics
- Prader–Willi Syndrome — clinical overview and treatment approaches
- Clinical trial phases — definitions and typical endpoints
- Nasdaq stock listing basics — trading hours and market structure
Appendix (select items)
Suggested appendices to maintain on an ongoing basis for SLNO stock monitoring:
- Historical price table (adjusted close, volume) — update monthly from Nasdaq data.
- Timeline of corporate events (trial readouts, filings, financings) — maintain with date and source.
- Clinical trial registry identifiers (NCT numbers) and trial status summaries.
- Glossary of technical terms used in this article (e.g., orphan drug, controlled‑release, topline results).
Notes on content sourcing and maintenance
Numerical stock metrics and analyst targets are time‑sensitive and should be updated from primary market data sources. Primary sources used for this entry include corporate press releases, SEC filings and major market data providers. Where a precise numeric value is required (market cap, volume, EPS), retrieve the latest figure from Nasdaq, SEC filings or the company’s investor relations materials and record the date accessed.
As of 2024‑06‑01, according to the company’s public filings and Nasdaq market data pages, Soleno’s corporate disclosures and trial status updates provide the baseline facts summarized above. For any trading decisions or detailed financial modeling, consult the most recent SEC filings and market quotes, and consider professional advice from licensed advisors.
Actionable next steps for readers
If you are tracking SLNO stock:
- Bookmark the company’s investor relations page and subscribe to press releases for timely updates.
- Monitor SEC EDGAR for filings that affect corporate structure, financings or material events.
- Follow clinical trial registries for status changes and posted results tied to trial identifiers.
- Use real‑time market data from Nasdaq and reputable charting platforms to track price and volume; for execution, consider Bitget as a regulated trading venue.
- Maintain a dated timeline of news and map events to price action to better understand historical volatility drivers.
Further exploration: Explore more about rare disease therapeutics, how regulatory review works for orphan drugs, and peer biotechs to build a comparative view of SLNO stock’s prospects.
Explore Bitget’s trading tools and Bitget Wallet for account setup and secure custody if you plan to trade equities or manage digital assets. Always verify account terms, fees, and regulatory coverage before transacting.
Disclaimer: This article is informational only and does not constitute investment, legal or tax advice. The scientific and financial information summarized here is based on public sources and should be independently verified. The content avoids speculation and limits statements to facts and high‑level descriptions; readers should consult primary sources for decisions.
